Wordt geladen...
Out-of-Pocket Costs for Infliximab and Its Biosimilar for Rheumatoid Arthritis Under Medicare Part D
This study estimates mean 2017 total and out-of-pocket costs for infliximab and its biosimilar infliximab-dyyb under Medicare Part D.
Bewaard in:
| Gepubliceerd in: | JAMA |
|---|---|
| Hoofdauteurs: | , , , , |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
American Medical Association
2018
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6142992/ https://ncbi.nlm.nih.gov/pubmed/30193264 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jama.2018.7316 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|